November 11, 2021 Clinical Research/Diagn.

CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease

Recommendation based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to moderate disease and reduced risk of symptomatic COVID-19 infections in people exposed to the virus Ronapreve’s combination approach continues to retain neutralisation activity against variants of concern Basel, 11 November 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today... Read more

November 4, 2021 Uncategorized

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces the repurchase of the equity stake held by Novartis in Roche

Roche and Novartis agree on the repurchase by Roche Holding Ltd of 53.3 million Roche shares from Novartis Holding AG. Repurchase is conditional upon the approval of a capital reduction by cancellation of the repurchased shares and the approval of the interim financial statements prepared for the purpose of the transaction by an Extraordinary General... Read more

October 29, 2021 PAI Top-10

IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer

IMPACT trial data shows clear benefit in using Roche’s CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by Infection with high-risk human papillomavirus (HPV). As recently published in... Read more

October 25, 2021 Atomic Spectroscopy Product Launch

Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. This is the first time that research scientists can conduct oncology research with Foundation Medicine’s comprehensive genomic profiling in their own laboratories to gain... Read more

October 22, 2021 Acad, Gov/Utilities

FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a month By continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with nAMD maintain their vision with as few as... Read more

October 22, 2021 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1 The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study. This new test expands Roche’s... Read more

October 15, 2021 Acad, Gov/Utilities

US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting Approval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with best supportive care Basel, 15 October 2021 – Roche (SIX: RO, ROG; OTCQX:... Read more

October 15, 2021 M&A, Partnerships

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment. Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs. Builds on Roche’s Digital Pathology Open Environment, expanding the company’s commitment to improving patient outcomes... Read more

October 14, 2021 PAI Top-10 Product Launch

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder

New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of people treated with ENSPRYNG remained relapse-free after four years in the SAkuraStar (73%) and SAkuraSky (71%) open-label extension (OLE) studies, with a favourable safety profile ENSPRYNG is now approved in 58... Read more